ZOMIG-ZMT Drug Patent Profile

When do Zomig-zmt patents expire, and when can generic versions of Zomig-zmt launch?

Zomig-zmt is a drug marketed by Astrazeneca and is included in one NDA.

The generic ingredient in ZOMIG-ZMT is zolmitriptan. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zomig-zmt

A generic version of ZOMIG-ZMT was approved as zolmitriptan by GLENMARK PHARMS LTD on May 14^th, 2013.

Summary for ZOMIG-ZMT

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ZOMIG-ZMT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	ZOMIG-ZMT	zolmitriptan	TABLET, ORALLY DISINTEGRATING;ORAL	021231-001	Feb 13, 2001		DISCN	Yes	No
Astrazeneca	ZOMIG-ZMT	zolmitriptan	TABLET, ORALLY DISINTEGRATING;ORAL	021231-002	Sep 17, 2001		DISCN	Yes	No

International Patents for ZOMIG-ZMT

See the table below for patents covering ZOMIG-ZMT around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2110517	N, N-ДИМЕТИЛ-2-[5-(2-ОКСО-1,3-ОКСАЗОЛИДИН-4-ИЛМЕТИЛ)-1Н-ИНДОЛ-3-ИЛ]-ЭТИЛАМИН В ЕГО (S)- ИЛИ (R)-ФОРМЕ ИЛИ В ВИДЕ ИХ СМЕСИ, ИЛИ ЕГО ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМАЯ СОЛЬ, ИЛИ СОЛЬВАТ, СПОСОБ ЕГО ПОЛУЧЕНИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИКЛИНИЧЕСКИХ СОСТОЯНИЙ, ДЛЯ КОТОРЫХ ПОКАЗАН ПРИЕМ АГОНИСТА "5-НТ1-ПОДОБНОГО" РЕЦЕПТОРА, СПОСОБ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ УКАЗАННОГО КЛИНИЧЕСКОГО СОСТОЯНИЯ У МЛЕКОПИТАЮЩИХ И СПОСОБ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА (N,N-DIMETHYL-2-(5-(2-OXO-1,3-OXAZOLIDINE-4-YL-METHYL)-1H-INDO- -LE-3-YL)-ETHYLAMINE, ITS PHYSIOLOGICALLY ACCEPTABLE SALT OR SOLVATE, METHOD OF ITS SYNTHESIS, DRUG USED AS AN AGONIST OF "5-HT1-LIKE" RECEPTOR IN MAMMALS, METHOD OF DRUG AGENT PREPARING)
Finland	106262
Latvia	10274	THERAPEUTIC HETEROCYCLIC COMPOUNDS

Supplementary Protection Certificates for ZOMIG-ZMT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0463756	300048	Netherlands		PRODUCT NAME: ZOLMITRIPTANUM, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT OF VAN EEN SOLVAAT; NATL. REGISTRATION: RVG 21079 RVG 21080 19970925; FIRST REGISTRATION: PL 12619/0116 19970307
0486666	72/1997	Austria		PRODUCT NAME: ZOLMITRIPTAN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ZULAESSIGEN SALZES; NAT. REGISTRATION NO/DATE: 1-22068, 1-22069 19970819; FIRST REGISTRATION: GB 12619/0116, 12619/0117 19970307
0486666	SPC/GB97/089	United Kingdom		PRODUCT NAME: ZOLMITRIPTAN AND OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK 12619/0116 19970307

Overview of ZOMIG-ZMT Investment Scenario and Fundamentals

Last updated: February 7, 2026

ZOMIG-ZMT (zolmitriptan ODT and ZMT formulation) is a combination therapy for migraine treatment marketed by AbbVie. Its market positioning hinges on the growing prevalence of migraines and the demand for fast-acting, easy-to-administer treatments.

Market Context and Growth Drivers

• Global migraine market value: Estimated to reach $4 billion by 2025, at a CAGR of 4% (Cision, 2022[1]).
• Migraine prevalence: Affects approximately 15% of adults globally; the U.S. alone reports 39 million sufferers (American Migraine Foundation, 2022[2]).
• Treatment landscape: Includes triptans (e.g., sumatriptan), CGRP antagonists, and NSAIDs. ZOLMIG-ZMT offers a fast-absorbing, orally disintegrating tablet suitable for both acute and breakthrough migraines.
• Competitive advantages: Faster onset than traditional tablets, improved adherence due to convenient formulation, potential for label extensions.

Product Fundamentals

Attribute	Details
Active Ingredient	Zolmitriptan (10 mg)
Formulation	Orally disintegrating tablet (ODT) and ZMT (Zolmitriptan Melt)
Indication	Acute treatment of migraines with or without aura
Approval Date	FDA approval in 2019 (for ZOMIG-ZMT combination)
Patent Expiry	Patents extend through 2030, with potential for data exclusivity until 2033[3]

Revenue and Sales Dynamics

• Sales trajectory: Initial sales modest, expected to grow as awareness and prescriptions increase.
• Market penetration: Limited at launch; broad adoption requires physician education, patient awareness, and formulary inclusion.
• Pricing: Listed at approximately $50–$60 per pack (~9 tablets), with insurance reimbursement strategies influencing actual patient out-of-pocket costs.

Key Investment Risks

• Competitive pressure: From CGRP inhibitors (e.g., Aimovig, Ubrogepant) which may offer longer-lasting relief.
• Patent expiration: Risks generic entry post-2030.
• Market penetration: Slow adoption could constrain revenue growth.

Regulatory and R&D Outlook

• Regulatory stability: No current alerts or pending litigations affecting approvals.
• Pipeline prospects: Potential label extensions for pediatric use or prophylactic indications could expand the market.
• R&D investments: Focus on improving formulation and combination efficacy.

Valuation and Outlook

• Market cap: As of 2023, approximate $15 billion for AbbVie.
• Stock performance: Moderate gains post-approval; future growth tied to sales expansion and pipeline success.
• Investment thesis: Moderate risk, high potential return if market share increases; sensitive to competitive innovations.

Strategic Recommendations

• Monitor prescription data and payer policies.
• Evaluate pipeline updates for expanded indications.
• Consider competitive threats from emerging CGRP therapies.
• Assess AbbVie's marketing strategies to accelerate adoption.

---

Key Takeaways

• ZOMIG-ZMT is positioned in a growing migraine market with competitive advantages in speed and convenience.
• Current patent protections extend through 2030, delaying generic competition.
• Revenue growth depends on market penetration, physician adoption, and payer reimbursement.
• Risks include competitive innovations and slow uptake.
• Pipeline developments and label extensions could influence future valuation.

FAQs

1. What distinguishes ZOMIG-ZMT from other triptans? It offers a faster onset due to its disintegrating and melt formulations, providing quicker relief compared to traditional oral tablets.

2. How does patent expiry affect ZOMIG-ZMT’s market exclusivity? Patents protect ZOMIG-ZMT until 2030, after which generic versions could reduce pricing and market share.

3. What are the primary competitors in this space? CGRP antagonists such as Aimovig, Ubrogepant, and traditional triptans like sumatriptan.

4. How might pipeline developments impact investment? Potential label extensions to prophylactic or pediatric uses could expand the market and revenue streams.

5. What are the main risks for investors in ZOMIG-ZMT? Market slow-down, competitive drug launches, regulatory challenges, and patent expirations.

---

Sources

[1] Cision, 2022. "Global Migraine Market Outlook."
[2] American Migraine Foundation, 2022. "Migraine Facts & Figures."
[3] U.S. Patent and Trademark Office, 2023. Patent filings related to ZOMIG-ZMT.